Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below ...

Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. The SPDR S&P ...

Discover why State Street SPDR S&P Biotech ETF (XBI) is up 30% YTD, its unique high-beta structure, and key risks for biotech investors.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...

On November 14, 2025, Bain Capital Life Sciences Investors, LLC, disclosed a full exit from Nuvalent ( NUVL +3.29%), reducing ...

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...